A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, non-randomized study in patients with advanced non-squamous
NSCLC.
Each cycle will be 21 days. Patients will be evaluated every 2 cycles (~6 weeks) for response
using RECIST criteria. Those patients achieving stable disease or better will continue
therapy. Those patients experiencing progressive disease will be taken off study.
Patients will receive 6 cycles of Eloxatin, Alimta, and Bevacizumab. After the 6 cycles,
patients will receive Bevacizumab alone every 21 days until evidence of disease progression
or unacceptable toxicity.
Note: Once patient has completed the 6 cycles of Eloxatin, Alimta, and Bevacizumab and is
receiving single-agent Bevacizumab, assessment of response will be performed every 3 cycles
(~every 9 weeks) using RECIST criteria.